Teh, Megan R. https://orcid.org/0000-0002-8095-9961
Gudgeon, Nancy https://orcid.org/0000-0002-0396-5241
Frost, Joe N. https://orcid.org/0000-0002-5946-6062
Sinclair, Linda V. https://orcid.org/0000-0003-1248-7189
Smith, Alastair L. https://orcid.org/0000-0001-6330-1407
Millington, Christopher L. https://orcid.org/0009-0007-9219-0946
Kronsteiner, Barbara https://orcid.org/0000-0003-0867-2867
Roberts, Jennie
Marzullo, Bryan P. https://orcid.org/0000-0002-1874-6906
Murray, Hannah
Preston, Alexandra E. https://orcid.org/0000-0003-0008-5916
Stavrou, Victoria https://orcid.org/0009-0009-3245-4967
Rehwinkel, Jan
Milne, Thomas A. https://orcid.org/0000-0002-0413-4271
Tennant, Daniel A. https://orcid.org/0000-0003-0499-2732
Dunachie, Susanna J. https://orcid.org/0000-0001-5665-6293
Armitage, Andrew E. https://orcid.org/0000-0001-5977-6602
Dimeloe, Sarah https://orcid.org/0000-0002-4598-6518
Drakesmith, Hal https://orcid.org/0000-0002-8503-6103
Funding for this research was provided by:
Wellcome Trust (205023/Z/16/Z)
Cancer Research UK (C42109/A24757)
RCUK | Medical Research Council (MCU_12010/10)
Article History
Received: 29 January 2024
Accepted: 19 May 2025
First Online: 20 June 2025
Competing interests
: T.A.M. is a paid consultant for and shareholder in Dark Blue Therapeutics Ltd. D.A.T. undertakes paid consultancy work for Sitryx Ltd. The remaining authors declare no competing interests.